Charles River Laboratories | CRL - Sales Revenues


Charles River Laboratories reported $995.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agilent USD 1.84B 37M Mar/2026
Align Technology USD 1.04B 10M Mar/2026
Bio-Rad Laboratories USD 592.1M 101.1M Mar/2026
Bruker USD 823.4M 153.8M Mar/2026
Cardinal Health USD 60.9B 4.73B Mar/2026
Charles River Laboratories USD 995.8M 1.6M Mar/2026
Cigna USD 68.52B 3.95B Mar/2026
Concord Medical Services Hldg CNY 200.61M 83.9M Jun/2025
CVS Health USD 100.4B 5.3B Mar/2026
Danaher USD 5.95B 890M Mar/2026
Dentsply International USD 880M 81M Mar/2026
Elevance Health USD 49.5B 200M Mar/2026
Humana USD 39.65B 7.13B Mar/2026
Illumina USD 1.09B 70M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Intrexon USD 717K 511K Jun/2024
IQVIA Holdings USD 4.15B 210M Mar/2026
Laboratory Of America USD 3.54B 20M Mar/2026
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Lonza CHF 3.58B 63M Jun/2025
McKesson USD 92.3B 13.86B Mar/2026
Merck EUR 5.13B 120M Mar/2026
Mettler Toledo International USD 947.13M 182.87M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Quest Diagnostics USD 2.9B 90M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
UnitedHealth USD 111.7B 1.5B Mar/2026
Veradigm USD 142.52M 9.38M Dec/2022
Waters USD 1.27B 338M Mar/2026
West Pharmaceutical Services USD 844.9M 39.9M Mar/2026